Literature DB >> 19351219

Developments in age-related macular degeneration: Diagnosis and treatment.

Steven R Kaufman1.   

Abstract

Age-related macular degeneration (ARMD) is the leading cause of legal blindness of Americans over age 65 years. Severe loss of vision is usually due to exudative ARMD, of which there are about 200,000 new cases in the United States annually. Until recently, only a small fraction of patients benefited from treatment, but advances in the early diagnosis of the disease and major developments in therapy have substantially improved the prognosis of patients with ARMD. Because visual loss substantially reduces quality of life, effective management of ARMD will have increasing public health importance as the population ages. The American Academy of Ophthalmology recommends that people over age 65 years should have a comprehensive eye examination every 1 to 2 years to check for cataracts, macular degeneration, glaucoma, and other conditions. Those who complain of difficulty reading, driving at night, or adapting from sunlight to indoor lighting might have macular degeneration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19351219

Source DB:  PubMed          Journal:  Geriatrics        ISSN: 0016-867X


  3 in total

1.  Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model.

Authors:  Carolyn K Pan; Chandrasekar Durairaj; Uday B Kompella; Ogechi Agwu; Scott C N Oliver; Hugo Quiroz-Mercado; Naresh Mandava; Jeffrey L Olson
Journal:  J Ocul Pharmacol Ther       Date:  2011-05-16       Impact factor: 2.671

2.  Design and in vitro biocompatibility of a novel ocular drug delivery device.

Authors:  Nathan Gooch; Randon Michael Burr; Dolly J Holt; Bruce Gale; Balamurali Ambati
Journal:  J Funct Biomater       Date:  2013-01-18

3.  Health insurance enrollment and vision health in rural China: an epidemiological survey.

Authors:  Xiaochang Yan; Baoqun Yao; Xi Chen; Shaoye Bo; Xuezheng Qin; Hua Yan
Journal:  BMC Health Serv Res       Date:  2021-07-31       Impact factor: 2.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.